FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
monucion I(D).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Nash Huw M. (Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE							2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK] 3. Date of Earliest Transaction (Month/Day/Year) 06/01/2021 4. If Amendment, Date of Original Filed (Month/Day/Year)									S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Street) BEDFORD MA 01730 (City) (State) (Zip)						3,7100								Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
		Tabl	e I - I	Non-Deriv	vative	Sec	uritie	es A	cquire	d, D	isposed o	of, or B	eneficia	ally (Owned	t .					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					1	Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefic Owned		es ially Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3		ction(s)			(Instr. 4)		
Common Stock 06/01/202						21		М		575	A	\$2.19		575		D					
Common Stock 06/01/202						21		S ⁽¹⁾		575	D	\$39.425	\$39.4252 ⁽²⁾		0		D				
		(e.g., peemed ation Date,	e.g., puts, c				s, opti	Ons Exercion D	cisable and					9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e C S F Illy C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
							and 5						Amount			(iiisiii 4)					
					Code	v		(D)	Date Exercis	sable	Expiration Date	Title	Number of Shares								
Employee Stock Option (Right to Buy)	\$2.19	06/01/2021			M			575	(3)		12/12/2028	Common Stock	575	4	\$0.00	124,822	2	D			

Explanation of Responses:

- $1. \ The \ sales \ reported \ on \ this \ Form \ 4 \ were \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ reporting \ person.$
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$39.17 to \$39.70 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

Remarks:

/s/ Stephen Tulipano, Attorneyin-Fact 06/03/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.